Researchers found that an experimental drug called diranersen may help slow cognitive decline in people with early Alzheimer’s disease. This drug targets tau, a protein that forms tangles in the brains of those with Alzheimer’s. In a recent study involving 416 participants with mild cognitive impairment or mild Alzheimer’s dementia, diranersen showed promising effects on both brain biomarkers and cognitive performance.

For those looking to age well, this study suggests that targeting tau could lead to meaningful improvements in memory and cognitive function. Participants who received the lowest dose of diranersen experienced a noticeable slowing of clinical decline, which is significant for anyone concerned about Alzheimer’s or related conditions. While the drug did not meet all its primary goals, the results indicate that it may still have a positive impact on brain health.

The CELIA study is in the early stages of research, specifically a Phase 2 trial, which means more studies are needed to confirm these findings. Although the results are encouraging, they are not yet definitive proof that diranersen will be effective for everyone. Biogen, the company behind the drug, plans to continue developing diranersen and will present more detailed findings in future scientific meetings.

If you are interested in brain health, staying informed about developments like diranersen could be beneficial. While it’s too early to take action based on this drug, maintaining a healthy lifestyle with regular exercise, a balanced diet, and mental stimulation remains essential for supporting cognitive function as you age.

Source: longevity.technology